# Kodiak Sciences Inc.: financial statements, quarterly

KOD · Nasdaq · CIK 1468748 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/kod.md) · [Financials](/companies/kod/financials.md) · [Filings](/companies/kod/filings.md) · [Insiders](/companies/kod/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/kod/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [36.2](/filings/0000950170-24-127059.md) | [46.6 d](/filings/0001193125-26-134887.md) | [29.9](/filings/0000950170-25-071523.md) | [32.5](/filings/0000950170-25-108033.md) | [31.9](/filings/0001193125-25-280183.md) | [31.8 d](/filings/0001193125-26-134887.md) | [43.6](/filings/0001193125-26-211951.md) | [42.8](/filings/0001193125-26-349251.md) | [50.5](/filings/0001193125-25-280183.md) | [45.5 d](/filings/0001193125-26-134887.md) | [48.5](/filings/0001193125-26-211951.md) | [56.1](/filings/0001193125-26-349251.md) |
| Operating income | $m | [(54.5)](/filings/0000950170-24-127059.md) | [(63.4) d](/filings/0001193125-26-134887.md) | [(46.1)](/filings/0000950170-25-071523.md) | [(48.0)](/filings/0000950170-25-108033.md) | [(46.6)](/filings/0001193125-25-280183.md) | [(46.2) d](/filings/0001193125-26-134887.md) | [(59.1)](/filings/0001193125-26-211951.md) | [(55.5)](/filings/0001193125-26-349251.md) | [(62.4)](/filings/0001193125-25-280183.md) | [(57.5) d](/filings/0001193125-26-134887.md) | [(59.8)](/filings/0001193125-26-211951.md) | [(66.8)](/filings/0001193125-26-349251.md) |
| Interest expense | $m | [0.0](/filings/0000950170-24-127059.md) | [0.0 d](/filings/0001193125-26-134887.md) | [0.0](/filings/0000950170-24-060483.md) | [0.0](/filings/0000950170-24-097010.md) | [0.0](/filings/0000950170-24-127059.md) | [0.0 d](/filings/0001193125-26-134887.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(50.0)](/filings/0000950170-24-127059.md) | [(59.5) d](/filings/0001193125-26-134887.md) | [(43.0)](/filings/0001193125-25-280183.md) | [(45.1)](/filings/0001193125-25-280183.md) | [(43.9)](/filings/0001193125-25-280183.md) | [(44.1) d](/filings/0001193125-26-134887.md) | [(57.5)](/filings/0001193125-26-349251.md) | [(54.3)](/filings/0001193125-26-349251.md) | [(61.5)](/filings/0001193125-25-280183.md) | [(56.7) d](/filings/0001193125-26-134887.md) | [(58.2)](/filings/0001193125-26-349251.md) | [(65.6)](/filings/0001193125-26-349251.md) |
| Diluted EPS | $ per share | [(0.95)](/filings/0000950170-24-127059.md) | not reported | [(0.82)](/filings/0000950170-25-071523.md) | [(0.86)](/filings/0000950170-25-108033.md) | [(0.84)](/filings/0001193125-25-280183.md) | not reported | [(1.09)](/filings/0001193125-26-211951.md) | [(1.03)](/filings/0001193125-26-349251.md) | [(1.16)](/filings/0001193125-25-280183.md) | not reported | [(0.94)](/filings/0001193125-26-211951.md) | [(1.05)](/filings/0001193125-26-349251.md) |
| Basic EPS | $ per share | [(0.95)](/filings/0000950170-24-127059.md) | not reported | [(0.82)](/filings/0000950170-25-071523.md) | [(0.86)](/filings/0000950170-25-108033.md) | [(0.84)](/filings/0001193125-25-280183.md) | not reported | [(1.09)](/filings/0001193125-26-211951.md) | [(1.03)](/filings/0001193125-26-349251.md) | [(1.16)](/filings/0001193125-25-280183.md) | not reported | [(0.94)](/filings/0001193125-26-211951.md) | [(1.05)](/filings/0001193125-26-349251.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [346](/filings/0000950170-24-127059.md) | [286](/filings/0001193125-26-134887.md) | [246](/filings/0000950170-25-071523.md) | [219](/filings/0000950170-25-108033.md) | [198](/filings/0001193125-25-280183.md) | [168](/filings/0001193125-26-134887.md) | [139](/filings/0001193125-26-211951.md) | [104](/filings/0001193125-26-349251.md) | [72.0](/filings/0001193125-25-280183.md) | [210](/filings/0001193125-26-349251.md) | [170](/filings/0001193125-26-211951.md) | [126](/filings/0001193125-26-349251.md) |
| Current assets | $m | [351](/filings/0000950170-23-063767.md) | [289](/filings/0000950170-25-046098.md) | [252](/filings/0000950170-24-060483.md) | [225](/filings/0000950170-24-097010.md) | [202](/filings/0000950170-24-127059.md) | [172](/filings/0001193125-26-134887.md) | [143](/filings/0000950170-25-071523.md) | [108](/filings/0000950170-25-108033.md) | [75.7](/filings/0001193125-25-280183.md) | [215](/filings/0001193125-26-349251.md) | [175](/filings/0001193125-26-211951.md) | [131](/filings/0001193125-26-349251.md) |
| Total assets | $m | [548](/filings/0000950170-23-063767.md) | [479](/filings/0000950170-25-046098.md) | [435](/filings/0000950170-24-060483.md) | [402](/filings/0000950170-24-097010.md) | [373](/filings/0000950170-24-127059.md) | [336](/filings/0001193125-26-134887.md) | [298](/filings/0000950170-25-071523.md) | [257](/filings/0000950170-25-108033.md) | [218](/filings/0001193125-25-280183.md) | [352](/filings/0001193125-26-349251.md) | [306](/filings/0001193125-26-211951.md) | [257](/filings/0001193125-26-349251.md) |
| Current liabilities | $m | [70.8](/filings/0000950170-23-063767.md) | [41.7](/filings/0000950170-25-046098.md) | [24.9](/filings/0000950170-24-060483.md) | [21.2](/filings/0000950170-24-097010.md) | [24.1](/filings/0000950170-24-127059.md) | [25.6](/filings/0001193125-26-134887.md) | [30.9](/filings/0000950170-25-071523.md) | [31.0](/filings/0000950170-25-108033.md) | [42.4](/filings/0001193125-25-280183.md) | [45.5](/filings/0001193125-26-349251.md) | [49.6](/filings/0001193125-26-211951.md) | [52.8](/filings/0001193125-26-349251.md) |
| Total liabilities | $m | [245](/filings/0000950170-23-063767.md) | [214](/filings/0000950170-25-046098.md) | [194](/filings/0000950170-24-060483.md) | [187](/filings/0000950170-24-097010.md) | [187](/filings/0000950170-24-127059.md) | [185](/filings/0001193125-26-134887.md) | [189](/filings/0000950170-25-071523.md) | [186](/filings/0000950170-25-108033.md) | [194](/filings/0001193125-25-280183.md) | [194](/filings/0001193125-26-349251.md) | [194](/filings/0001193125-26-211951.md) | [196](/filings/0001193125-26-349251.md) |
| Shareholders' equity | $m | [302](/filings/0000950170-24-127059.md) | [266](/filings/0001193125-26-134887.md) | [241](/filings/0001193125-25-280183.md) | [215](/filings/0001193125-25-280183.md) | [185](/filings/0001193125-25-280183.md) | [150](/filings/0001193125-26-349251.md) | [109](/filings/0001193125-26-349251.md) | [70.3](/filings/0001193125-26-349251.md) | [23.7](/filings/0001193125-25-280183.md) | [157](/filings/0001193125-26-349251.md) | [112](/filings/0001193125-26-349251.md) | [61.1](/filings/0001193125-26-349251.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(32.8) d](/filings/0000950170-24-127059.md) | [(32.2) d](/filings/0001193125-26-134887.md) | [(39.6)](/filings/0000950170-25-071523.md) | [(26.5) d](/filings/0000950170-25-108033.md) | [(21.2) d](/filings/0001193125-25-280183.md) | [(30.1) d](/filings/0001193125-26-134887.md) | [(29.1)](/filings/0001193125-26-211951.md) | [(34.7) d](/filings/0001193125-26-349251.md) | [(32.9) d](/filings/0001193125-25-280183.md) | [(39.4) d](/filings/0001193125-26-134887.md) | [(40.0)](/filings/0001193125-26-211951.md) | [(46.2) d](/filings/0001193125-26-349251.md) |
| Capital expenditure | $m | [0.2 d](/filings/0000950170-24-127059.md) | [27.5 d](/filings/0001193125-26-134887.md) | [0.0](/filings/0000950170-25-071523.md) | [0.0 d](/filings/0000950170-25-108033.md) | [0.2 d](/filings/0001193125-25-280183.md) | [0.1 d](/filings/0001193125-26-134887.md) | [0.3](/filings/0001193125-26-211951.md) | [0.1 d](/filings/0001193125-26-349251.md) | [0.1 d](/filings/0001193125-25-280183.md) | [0.0 d](/filings/0001193125-26-134887.md) | [0.9](/filings/0001193125-26-211951.md) | [0.4 d](/filings/0001193125-26-349251.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [52.3](/filings/0000950170-23-063767.md) | [52.3](/filings/0000950170-24-060483.md) | [52.4](/filings/0000950170-24-097010.md) | [52.5](/filings/0000950170-24-127059.md) | [52.5](/filings/0000950170-25-071523.md) | [52.6](/filings/0000950170-25-108033.md) | [52.6](/filings/0001193125-25-280183.md) | [52.7](/filings/0001193125-26-211951.md) | [52.8](/filings/0001193125-26-349251.md) | [52.9](/filings/0001193125-25-280183.md) | [61.9](/filings/0001193125-26-211951.md) | [62.6](/filings/0001193125-26-349251.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 62,849,457 at 2026-08-06, from the cover of the [10-Q filed 2026-08-13](/filings/0001193125-26-349251.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.